Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cited by
Items 201–300 of 567
Mutually Exclusive Inactivation of DMP1 and ARF/p53 in Lung Cancer
Mallakin, A., Sugiyama, T., Taneja, P., Matise, L. A., Frazier, D. P., Choudhary, M., Hawkins, G. A., D'Agostino, R. B., Willingham, M. C., & Inoue, K. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.034 · Cited by 80
“Haploid insufficiency of p19Arf has been reported in murine solid tumors only when p16Ink4a was homozygously inactivated (Krimpenfort et al., 2001).”
BackgroundPathways to Melanoma Development: Lessons from the Mouse
Walker, G. J., & Hayward, N. K. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00217.x · Cited by 83
Dlugosz, A. A., Merlino, G. T., & Yuspa, S. H. (2002) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1523-1747.2002.19631.x · Cited by 81
“…inactivating mutations, or the Cdk4 R24C mutation described in patients with familial CMM, were reported to be susceptible to DMBAinduced melanoma (Krimpenfort et al, 2001; Sharpless et al, 2001; Sotillo et al, 2001; Rane et al, 2002), strongly supporting a role for the p16INK4a/Cdk4/Rb pathway…”
BackgroundCarrasco, D. R., Fenton, T. R., Sukhdeo, K., Protopopova, M., Enos, M., You, M. J., Divicio, D., Nogueira, C., Stommel, J. M., Pinkus, G. S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.028 · Cited by 75
“…show increased incidence of spontaneous and carcinogen-induced cancers including softtissue sarcomas, melanoma, and splenic histiocytic lymphomas (Krimpenfort et al., 2001; Sharpless et al., 2001), thereby demonstrating that both gene products encoded by this locus exert important and…”
BackgroundThe Role of p16INK4a Pathway in Human Epidermal Stem Cell Self-Renewal, Aging and Cancer
D’Arcangelo, D., Tinaburri, L., & Dellambra, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071591 · Cited by 85
“The 16INK4a gene is frequently mutated in human cancers [20] and mice lacking 16INK4a are prone to spontaneous or induced tumorigenesis [151,152].”
BackgroundOkuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Role of Epidermal Growth Factor Receptor Signaling in RAS-Driven Melanoma
Bardeesy, N. M., Kim, M., Xu, J., Kim, R.-S., Shen, Q. “., Bosenberg, M., Wong, W. H., & Chin, L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.10.4176-4188.2005 · Cited by 81
“Mice deficient in Ink4a/Arf are also prone to the development of melanomas after carcinogen treatment (34, 54).”
BackgroundDDB1-CUL4 and MLL1 Mediate Oncogene-Induced p16 INK4a Activation
Kotake, Y., Zeng, Y., & Xiong, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2739 · Cited by 69
“spontaneous cancers (3, 4) and have a reduced decline of stem and progenitor cell function during aging (5–7).”
Markers of cellular senescence.
Carnero, A. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_4 · Cited by 68
Stepanova, L., & Sorrentino, B. P. (2005) · Blood · doi:10.1182/blood-2004-06-2242 · Cited by 68
Garcia-Diaz, C., Pöysti, A., Mereu, E., Clements, M., Brooks, L. J., Gálvez‐Cancino, F., Castillo, S. P., Tang, W., Beattie, G., Courtot, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112472 · Cited by 76
“Berns (Cdkn2).(79) Trp53 pups were used for modeling Nf1 and Pdgfr tumor models, Cdkn2a mice were used for the EGFR model.”
MethodSmeds, J., Berggren, P., Ma, X., Xu, Z., Hemminki, K., & Kumar, R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.645 · Cited by 71
Genes and pathways driving glioblastomas in humans and murine disease models
Merlo, A. (2003) · Neurosurgical Review · doi:10.1007/s10143-003-0267-8 · Cited by 75
Molecular genetics of neuroendocrine tumors
Duerr, E., & Chung, D. C. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.12.001 · Cited by 70
Khalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 74
Haploinsufficient tumor suppressor genes.
Inoue, K., & Fry, E. A. (2017) · PubMed · Cited by 85
Laud, K., Marian, C., Avril, M.-F., Barrois, M., Chompret, A., Goldstein, A. M., Tucker, M. A., Clark, P. A., Peters, G., Chaudru, V., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.033498 · Cited by 73
“[19] Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A.”
BackgroundJirawatnotai, S., Moons, D. S., Stocco, C. O., Franks, R. R., Hales, D. B., Gibori, G., & Kiyokawa, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301206200 · Cited by 69
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Chung, W.-J., Daemen, A., Cheng, J. H., Long, J. E., Cooper, J. E., Wang, B.-E., Tran, C., Singh, M., Gnad, F., Modrusan, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708391114 · Cited by 63
Chemotherapy response and resistance
Lee, S., & Schmitt, C. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00014-x · Cited by 73
p16(INK4a) and p53 deficiency cooperate in tumorigenesis.
Sharpless, N. E., Alson, S., Chan, S., Silver, D. P., Castrillón, D. H., & DePinho, R. A. (2002) · PubMed · Cited by 83
Loss of p16 expression is associated with histological features of melanoma invasion
Pavey, S. J., Cummings, M. C., Whiteman, D. C., Castellano, M., Walsh, M. D., Gabrielli, B. G., Green, A. C., & Hayward, N. K. (2002) · Melanoma Research · doi:10.1097/00008390-200212000-00003 · Cited by 66
Simin, K., Wu, H., Lu, L., Pinkel, D., Albertson, D., Cardiff, R. D., & Dyke, T. V. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020022 · Cited by 62
“Despite the prevalence of pRb pathway defects in human sporadic cancers, mice harboring germline mutations of p16INK4a do not develop mammary cancer (Krimpenfort et al. 2001; Sharpless et al. 2001).”
BackgroundHuber, G. F., Albinger‐Hegyi, A., Soltermann, A., Roessle, M., Graf, N., Haerle, S. K., Holzmann, D., Moch, H., & Hegyi, I. (2011) · Cancer · doi:10.1002/cncr.26100 · Cited by 71
G‐protein‐coupled receptors and melanoma
Lee, H. J., Wall, B., & Chen, S. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00478.x · Cited by 78
“…carcinogenesis protocols in several mouse model systems (Bradl et al., 1991; Chin et al., 1997; Iwamoto et al., 1991; Kato et al., 1998; Klein- Szanto et al., 1994; Krimpenfort et al., 2001; Mintz et al., 1993; Noonan et al., 2003; Otsuka et al., 1998; Powell et al., 1999; Takayama et al., 1997).”
BackgroundSherr, C. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00486-x · Cited by 78
Lloyd, A. C. (2002) · Nature Cell Biology · doi:10.1038/ncb0202-e25 · Cited by 86
Chapman, E., Harnden, P., Chambers, P. A., Johnston, C., & Knowles, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0411 · Cited by 63
Ramsey, M. R., Krishnamurthy, J., Pei, X.-H., Torrice, C., Lin, W., Carrasco, D. R., Ligon, K. L., Xiong, Y., & Sharpless, N. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3437 · Cited by 61
“Wild-type MEFs show significant expression of p16 that markedly increases with serial passage (26, 27); yet, p16-deficient MEFs enter senescence with identical kinetics as wild-type cells (17, 18).”
Ohtani, N., Yamakoshi, K., Takahashi, A., & Hara, E. (2010) · Cell Division · doi:10.1186/1747-1028-5-1 · Cited by 62
Genetic and environmental factors in cutaneous malignant melanoma
Paillerets, B. B., Avril, M., Chompret, A., & Démenais, F. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01360-8 · Cited by 60
Chen, Y., Klimstra, D. S., Mongeau, M. E., Tatem, J. L., Boyartchuk, V., & Lewis, B. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0381 · Cited by 63
Inoue-Narita, T., Hamada, K., Sasaki, T., Hatakeyama, S., Fujita, S., Kawahara, K., Sasaki, M., Kishimoto, H., Eguchi, S., Kojima, I., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0889 · Cited by 59
“To date, double mutations of p16 / /p19 (42) or p53 / /H-Ras (43) or triple mutations of H-Ras/p16 / /p19 / (44), N-Ras/ p16 / /p19 / (45), or Pten p16 / /p19 / (46) have been necessary to reliably induce melanomas in mice.”
BackgroundCellular signaling in normal and cancerous stem cells
Grinstein, E., & Wernet, P. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.021 · Cited by 61
CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1
Deng, H., Liu, J., Deng, Y., Han, G., Shellman, Y. G., Robinson, S. E., Tentler, J. J., Robinson, W. A., Norris, D. A., Wang, X., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.487 · Cited by 56
“As a well known tumor suppressor of melanoma (Krimpenfort et al., 2001; Monahan et al., 2010; J Invest Dermatol.”
BackgroundAge-Specific Functional Epigenetic Changes in p21 and p16 in Injury-Activated Satellite Cells
Li, J., Han, S., Cousin, W., & Conboy, I. M. (2015) · Stem Cells · doi:10.1002/stem.1908 · Cited by 56
Takaoka, M., Harada, H., Deramaudt, T. B., Oyama, K., Andl, C. D., Johnstone, C. N., Rhoades, B., Enders, G. H., Opitz, O. G., & Nakagawa, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207923 · Cited by 63
“However, p16INK4a is not required for Ha-RasG12V-induced premature senescence as p16INK4adeficient mouse embryonic fibroblasts still undergo senescence and are arrested by oncogenic Ras (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundTalluri, S., Isaac, C. E., Ahmad, M., Henley, S. A., Francis, S. M., Martens, A. L., Bremner, R., & Dick, F. A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01168-09 · Cited by 55
“Other genetically modified strains of mice whose lesions completely abrogate this senescence arrest pathway, such as Ink4a / mutant mice, already have surprisingly low rates of spontaneous tumorigenesis themselves (31, 52).”
BackgroundRb/E2F: A two-edged sword in the melanocytic system
Halaban, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1582-z · Cited by 61
Tormo, D., Ferrer, A., Gaffal, E., Wenzel, J., Basner‐Tschakarjan, E., Steitz, J., Heukamp, L. C., Gütgemann, I., Buettner, R., Malumbres, M., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060017 · Cited by 61
“Deletion of the p16/INK4a protein using knockout strategies predisposes mice for the development of melanoma.(7,8) A similar phenotype has been observed in mice carrying a mutated CDK4 gene”
BackgroundSin3B Expression Is Required for Cellular Senescence and Is Up-regulated upon Oncogenic Stress
Grandinetti, K. B., Jelinic, P., DiMauro, T., Pellegrino, J., Fernández Rodríguez, R., Finnerty, P. M., Ruoff, R., Bardeesy, N., Logan, S. K., & David, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0537 · Cited by 54
Frequent alterations in p16/ CDKN2A identified by immunohistochemistry and FISH in chordoma
Cottone, L., Eden, N., Usher, I., Lombard, P., Ye, H., Ligammari, L., Lindsay, D., Brandner, S., Pižem, J., Pillay, N., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.156 · Cited by 55
“Germline mutations in CDKN2A confer susceptibility to melanoma and other tumours [12,13], and haploinsufficiency of p14 has been implicated in genetic models of various cancers [12,14].”
BackgroundMaurelli, R., Zambruno, G., Guerra, L., Abbruzzese, C., Dimri, G. P., Gellini, M., Bondanza, S., & Dellambra, E. (2006) · The FASEB Journal · doi:10.1096/fj.05-4480fje · Cited by 56
Polycomb Group Proteins Are Key Regulators of Keratinocyte Function
Eckert, R. L., Adhikary, G., Rorke, E. A., Chew, Y. C., & Balasubramanian, S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.318 · Cited by 55
“Consistent with this role, cells in p16 knockout mice are more susceptible to malignant progression (Krimpenfort et al., 2001; Sharpless et al., 2001).”
Evolutionary etiology of high-grade astrocytomas
Song, Y., Zhang, Q., Kutlu, B., Difilippantonio, S., Bash, R., Gilbert, D. J., Yin, C., O’Sullivan, T. N., Yang, C., Козлов, С. В., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317026110 · Cited by 59
Sotillo, R., Renner, O., Dubus, P., Ruiz-Cabello, J., Martín-Caballero, J., Barbacid, M., Carnero, A., & Malumbres, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4195 · Cited by 53
p16INK4A Positively Regulates Cyclin D1 and E2F1 through Negative Control of AUF1
Al‐Khalaf, H. H., Çolak, D., Al‐Saif, M., AlBakheet, A., Hendrayani, S., Al‐Yousef, N., Kaya, N., Khabar, K. S. A., & Aboussekhra, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021111 · Cited by 57
Tchernev, G., & Orfanos, C. E. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00700.x · Cited by 52
A unique role of the DNA fragmentation factor in maintaining genomic stability
Yan, B., Wang, H., Peng, Y., Hu, Y., Wang, H., Zhang, X., Chen, Q., Bedford, J. S., Dewhirst, M. W., & Li, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507779103 · Cited by 52
BERMAN, H., ZHANG, J., CRAWFORD, Y. G., GAUTHIER, M. L., FORDYCE, C. A., McDERMOTT, K. M., SIGAROUDINIA, M., KOZAKIEWICZ, K., & TLSTY, T. D. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.051 · Cited by 51
“The dissection of the contribution of these two loci in the initiation and progression of different cancers has demonstrated that loss of p16INK4a alone (with retention of p19Arf) leads to tumor predisposition in mice (Krinferpot et al. 2001).”
BackgroundAn Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen
Huijbers, I. J., Krimpenfort, P., Chomez, P., van der Valk, M. A., Song, J., Inderberg, E. M., Schmitt‐Verhulst, A., Berns, A. J. M., & den Eynde, B. J. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3216 · Cited by 59
“exons 2 and 3 of the Ink4a/Arf gene flanked by loxP sites (23) and are of”
Self-citationSpontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice
Hacker, E., Muller, H. K., Irwin, N., Gabrielli, B., Lincoln, D., Pavey, S., Powell, M. B., Malumbres, M., Barbacid, M., Hayward, N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3196 · Cited by 51
p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control
Bai, F., Pei, X., Pandolfi, P. P., & Xiong, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00266-06 · Cited by 53
Human tumor suppressor ARF impedes S-phase progression independent of p53.
Yarbrough, W. G., Bessho, M., Zanation, A. M., Bisi, J., & Xiong, Y. (2002) · PubMed · Cited by 70
Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 52
Aberrant expression of p16INK4a in human cancers – a new biomarker?
Inoue, K., & Fry, E. A. (2018) · Cancer Reports and Reviews · doi:10.15761/crr.1000145 · Cited by 55
Is there a role for genetic testing in patients with melanoma?
Kefford, R. F., & Mann, G. J. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200303000-00007 · Cited by 51
Kim, M. S., Kim, K. H., Lee, E. H., Lee, Y. M., Lee, S.-H., Kim, H. D., & Kim, Y. Z. (2014) · Journal of neurosurgery · doi:10.3171/2014.7.jns132661 · Cited by 50
Kato, S., Schwaederle, M. C., Daniels, G. A., Piccioni, D. E., Kesari, S., Bazhenova, L. A., Shimabukuro, K. A., Parker, B. A., Fanta, P. T., & Kurzrock, R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1014149 · Cited by 55
“In preclinical models, CDKN2A-mutant mice had accelerated tumorigenesis with increased incidence of metastases.(25) Also, in patients with head and neck cancer, increased ratios of CCND1: CDKN2A evaluated by polymerase chain reaction was significantly associated with metastases.”
BackgroundFamilial melanoma: a complex disorder leading to controversy on DNA testing
de Snoo, F. A., Bergman, W., & Gruis, N. A. (2003) · Familial Cancer · doi:10.1023/a:1025758527675 · Cited by 49
The Role of Cyclic-AMP Binding Protein (CREB) in Leukemia Cell Proliferation and Acute Leukemias
Shankar, D. B., & Sakamoto, K. M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000151095 · Cited by 54
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis
Moore, L., Venkatachalam, S., Vogel, H., Watt, J. C., Wu, C.-L., Steinman, H., Jones, S. N., & Donehower, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206985 · Cited by 48
“That both proteins are potent tumor suppressors is confirmed by the fact that inactivation of both or each individually results in early tumor formation in genetically modified mice (Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundCellular Senescence and Periodontitis: Mechanisms and Therapeutics
Chen, S., Zhou, D., Liu, O., Chen, H., Wang, Y., & Zhou, Y. (2022) · Biology · doi:10.3390/biology11101419 · Cited by 65
Targeting malignant melanoma with physical plasmas
Pasqual-Melo, G., Gandhirajan, R. K., Stoffels, I., & Bekeschus, S. (2018) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2018.03.001 · Cited by 49
Melanomagenesis: Overcoming the barrier of melanocyte senescence
Ha, L., Merlino, G., & Sviderskaya, E. V. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6230 · Cited by 47
The Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Oncogene-induced senescence: An essential role for Runx
Terry, A., Cameron, E., Neil, J., & Kilbey, A. (2008) · Cell Cycle · doi:10.4161/cc.6368 · Cited by 46
Wang, J., Zheng, B., Li, X., Nokelainen, K., Ångström, T., Lindström, M. S., & Wallin, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800308 · Cited by 53
Cooperation between p53 and p130(Rb2) in induction of cellular senescence
Kapic, A., Helmbold, H., Reimer, R. A., Klotzsche, O., Deppert, W., & Bohn, W. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401756 · Cited by 50
Genetic Evidence for Functional Dependency of p18Ink4c on Cdk4
Pei, X.-H., Bai, F., Tsutsui, T., Kiyokawa, H., & Xiong, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6653-6664.2004 · Cited by 45
Cellular Senescence as a Target in Cancer Control
Vergel, M., Marin, J. J., Estevez, P., & Carnero, A. (2011) · Journal of Aging Research · doi:10.4061/2011/725365 · Cited by 44
miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma
Põlajeva, J., Swartling, F. J., Jiang, Y., Singh, U., Pietras, K., Uhrbom, L., Westermark, B., & Roswall, P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-378 · Cited by 46
“Mouse glioma cell cultures were established from RCAS/ PDGFB-induced gliomas in a wild type, p16, p19 or p16/p19 background [21-27].”
MethodTargeting senescence to delay progression of multiple sclerosis
Oost, W., Talma, N., Meilof, J. F., & Laman, J. D. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1686-x · Cited by 49
Essential Roles of Cohesin STAG2 in Mouse Embryonic Development and Adult Tissue Homeostasis
Koninck, M. D., Lapi, E., Badía-Careaga, C., Cossío, I., Giménez-Llorente, D., Rodríguez-Corsino, M., Andrada, E., Hidalgo, A., Manzanares, M., Real, F. X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108014 · Cited by 51
Transgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes
Taneja, P., Zhu, S., Maglic, D., Fry, E. A., Kendig, R. D., & Inoue, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7516 · Cited by 50
Wolff, L., Garin, M. T., Koller, R. P., Bies, J., Liao, W., Malumbres, M., Tessarollo, L., Powell, D., & Perella, C. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207092 · Cited by 46
“Interestingly, it was similarly found that loss of p16Ink4a has a mild tumor-suppressor phenotype by itself (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundThe absence ofPrep1causes p53-dependent apoptosis of mouse pluripotent epiblast cells
Fernández, L. C., Laurent, A., Girasoli, S., Turco, M. Y., Longobardi, E., Iotti, G., Jenkins, N. A., Fiorenza, M. T., Copeland, N. G., & Blasi, F. (2010) · Development · doi:10.1242/dev.050567 · Cited by 46
“We crossed ink4Ap16-null (Krimpenfort et al., 2001) with Prep1+/–p53+/– double heterozygous mice.”
MethodHuman-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 47
“1Brn ( Cdkn2a KO ) 49 , Pten tm2Mak ( Pten fl ) 50 , Gt(Rosa)26Sor tm1(Notch1)Dam ( R26 LSL-NICD ) 51 , Kras tm4Tyj ( Kras G12D ) 52 , Cdkn1a tm1Led ( Cdkn1a KO ) 53 , Axin1 fl (ref.”
p16INK4A Positively Regulates p21WAF1 Expression by suppressing AUF1-dependent mRNA decay
Al‐Khalaf, H. H., & Aboussekhra, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070133 · Cited by 43
“particularly after exposure to carcinogens [16,17].”
Cell Cycle and Cancer: Genetic Analysis of the Role of Cyclin-dependent Kinases
Barbacid, M., Ortega, S., Sotillo, R., Odajima, J., Martín, A., Santamaría, D., Dubus, P. R., & Malumbres, M. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.005 · Cited by 46
“Other mutations, such as those ablating the INK4 inhibitors p16Ink4a and p15Ink4b, have not led to overt tumor development (Latres et al. 2000; Krimpenfort et al. 2001; Sharpless et al. 2001) but seem to predispose to cancer.”
p16INK4A and p14ARF tumour suppressors in melanoma: lessons from the mouse
Walker, G. J., & Hayward, N. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07271-9 · Cited by 41
Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression
Quereda, V., Martinalbo, J., Dubus, P. R., Carnero, A., & Malumbres, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210578 · Cited by 44
“Mice deficient in either p16INK4a, p15INK4b, p18INK4c or p21Cip1 have only a limited susceptibility to tumor development in aged mice (Latres et al., 2000; Krimpenfort et al., 2001; Martin-Caballero et al., 2001; Sharpless et al., 2001).”
BackgroundInfluentialAP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene
Ameyar‐Zazoua, M., Wisniewska, M. B., Bakiri, L., Wagner, E. F., Yaniv, M., & Weitzman, J. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208424 · Cited by 58
“Disabling ARF function alone allows cells to bypass senescence and is necessary for the immortalization of MEFs, mouse pre-B cells, keratinocytes and astrocytes, whereas loss of p16INK4A in human fibroblasts or in MEFs does not bypass senescence (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundDPY30 regulates pathways in cellular senescence through ID protein expression
Simboeck, E., Gutiérrez, A., Cozzuto, L., Beringer, M., Caizzi, L., Keyes, W. M., & Croce, L. D. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.159 · Cited by 40
“…(OIS) is induced by various cancer-causing cellular stresses, including oxidative stress, activation of oncogenes, and inactivation of tumour suppressor genes, and is therefore considered to be an important barrier to cellular transformation (Krimpenfort et al , 2001; Sharpless et al , 2001).”
Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression
Kabir, F. M. L., Alvarez, C. E., & Bird, R. (2015) · Veterinary Sciences · doi:10.3390/vetsci3010001 · Cited by 47
“Mice with targeted deletions of p16, p19ARF or both were investigated by several groups suggesting that mouse strains with specific inactivation of p16 or p19ARF were tumor prone but neither genetic loss alone was as severe as those with double knockouts of both of these genes [57,73–75].”
Backgroundvan Schanke, A., van Venrooij, G. M. C. A. L., Jongsma, M. J., Banus, H. A., Mullenders, L. H. F., van Kranen, H. J., & de Gruijl, F. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2476 · Cited by 38
Negishi, M., Saraya, A., Mochizuki, S., Helin, K., Koseki, H., & Iwama, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012373 · Cited by 36
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
“Loss of p16 reduces age-dependent defects in hematopoietic stem cell repopulation and apoptosis under stress (Krimpenfort et al. 2001; Janzen et al. 2006; Sato et al. 2015).”
BackgroundLee, M., Choi, B. Y., Cho, Y., Lee, S., Huang, Z., Kundu, J. K., Kim, M. O., Kim, D. J., Bode, A. M., Surh, Y., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.113613 · Cited by 42
“A dysfunctional p16INK4a protein results in the deregulation of the Rb and p53 tumor-suppressor signaling pathways in a wide variety of human cancers (Caldas et al., 1994; Krimpenfort et al., 2001; Sherr, 2001).”
Natural History of Meningioma Development in Mice Reveals: A Synergy ofNf2andp16Ink4aMutations
Kalamarides, M., Stemmer-Rachamimov, A. O., Takahashi, M., Han, Z., Chareyre, F., Niwa‐Kawakita, M., Black, P. M., Carroll, R. S., & Giovannini, M. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00105.x · Cited by 38
Driving the Cell Cycle to Cancer
Malumbres, M., Hunt, S. L., Sotillo, R., Martín‐Broto, J., Odajima, J., Martín, A., Dubus, P. R., Ortega, S., & Barbacid, M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_1 · Cited by 37
Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2
Palmero, I., Murga, M., Zubiaga, A. M., & Serrano, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205371 · Cited by 46
“…that, compared to the ARF/p53 pathway, the pathway controlled by Rb plays a secondary role in senescence and sensitivity to oncogenic stress in mouse ®broblasts (Dannenberg et al., 2000; Sage et al., 2000; Krimpenfort et al., 2001; Peeper et al., 2001; Sharpless et al., 2001; Sherr, 2001a).”
BackgroundPirin Inhibits Cellular Senescence in Melanocytic Cells
Licciulli, S., Luise, C., Scafetta, G., Capra, M. C., Giardina, G., Nuciforo, P. G., Bòsari, S., Viale, G., Mazzarol, G., Tonelli, C., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.019 · Cited by 38
Braden, W. A., Lenihan, J. M., Lan, Z., Luce, K. S., Zagorski, W., Bosco, E., Reed, M. F., Cook, J. G., & Knudsen, E. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00045-06 · Cited by 35
“Using primary fibroblasts deficient for p16ink4a, no significant effects on DNA replication have been observed (35, 61).”
BackgroundRetractedComparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma
Olvedy, M., Tisserand, J. C., Luciani, F., Boeckx, B., Wouters, J., Lopez, S., Rambow, F., Aibar, S., Thienpont, B., Barra, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91291 · Cited by 39
Disruptive chemicals, senescence and immortality
Carnero, A., Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. F., Mondello, C., Scovassi, A. I., Bisson, W. H., Amedei, A., Roy, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv029 · Cited by 29
The genetics of malignant melanoma
Lomas, J., Martín‐Duque, P., Pons, M., & Quintanilla, M. (2008) · Frontiers in bioscience · doi:10.2741/3065 · Cited by 40
“Moreover, treatment with DMBA of p16Ink4a-deficient mice that were heterozygous for p19Arf resulted in increased incidence of cutaneous melanoma that produced frequent metastasis (124).”
BackgroundKool, J., Uren, A. G., Martins, C. P., Sie, D., de Ridder, J., Turner, G., van Uitert, M., Matentzoglu, K., Lagcher, W., Krimpenfort, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2736 · Cited by 34
“Germline knockout studies have shown that loss of p15 and p16 predisposes mice for tumor development, confirming their role as tumor suppressor genes (7-10).”
Self-citationDisruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice
Coré, N., Joly, F., Boned, A., & Djabali, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207998 · Cited by 37
“Mice, specifically lacking p16INK4a, develop normally, except for a thymic hyperplasia which was most marked in the double-positive compartment (Krimpenfort et al., 2001).”
BackgroundYang, J., Luan, J., Yu, Y., Li, C., DePinho, R. A., Chin, L., & Richmond, A. J. (2001) · PubMed · Cited by 35
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.